Helvoet Pharma pumps in Rs 120 crore for Pune plant

Image
BS Reporter Mumbai/ Pune
Last Updated : Jan 20 2013 | 1:18 AM IST

Belgium based Helvoet Pharma, part of the Daetwyler Group is setting up its first greenfield production facility in Khandala Industrial Area, phase I (SEZ), on Pune- Bangalore Highway, near Pune. This is Helvoet Pharma’s first plant in India. The company has invested Rs 120 crore for the plant.

The plant will manufacture components for primary packaging of parenteral pharmaceutical and diagnostic drugs and will produce four billion components at full capacity by end of 2014 and one billion in the first year. Products manufactured in Pune plant will be exported to US and other European markets.

With 100 employees, the plant will be operational by 2012, the new facility will cater to the needs of the local pharmaceutical industry and globally operating pharmaceutical customers in India and other markets.

Speaking on this Paul J. Haelg, CEO and head technical components, Daetwyler Group said, “Helvoet Pharma’s decision to build its own manufacturing plant in India has been made to leverage the country’s position as the centre of excellence for generic and branded pharmaceutical products. India has the highest number of US FDA approved plants outside the USA and is expected to become a significant health care consumer market and has set a benchmark in this market.”

“Our confidence in the Indian market is reflected in our long association with the country and reflects the next step of our company’s global business growth strategy. Our engagement dates back to 1991 when we started collaboration in India for distribution of our products,” Guido Wallraff, head pharmaceutical packaging division, Daetwyler Group said.

Helvoet Pharma, a global supplier of primary and secondary pharmaceutical packaging components, was founded in 1970.

The company is headquartered in Belgium and has additional manufacturing facilities located in Europe, the USA and Asia, supplying over 10 billion parts to the pharmaceutical industry every year.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Sep 25 2010 | 12:59 AM IST

Next Story